Tezspire meets primary endpoints in Phase III EoE trial CROSSING
AstraZeneca and Amgen said the drug showed durable, statistically significant benefits over placebo in eosinophilic esophagitis through week 52.
SEC filing
Latest
22 stories
Tuesday, September 29
Wednesday, September 23
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability study
Friday, September 11
Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trial
Friday, September 4
Amgen registers Phase 4 trial testing Repatha's effect on coronary plaque burden
Friday, August 28
Amgen posts results for rocatinlimab AD trial, daxdilimab myositis study; mCRPC trial terminated
Thursday, August 27
Friday, August 21
Amgen registers Phase 3 trial comparing subcutaneous and IV tarlatamab in relapsed ES-SCLC
Tuesday, August 18
Amgen terminates Crohn's disease collaboration with TScan Therapeutics
Amgen notified TScan on August 12, 2026 that it is exiting their research agreement, effective November 10, 2026.
SEC filing
Tuesday, August 11
Mineralys reports Q2 2026 results, names new CMO ahead of lorundrostat PDUFA date
The FDA's target decision date for lorundrostat is December 22, 2026, and Mineralys says commercial launch preparations remain on schedule.
SEC filing
Thursday, August 6
Amgen posts ROCKET-SHUTTLE Phase 3 rocatinlimab results; Neulasta label updated; AMG 691 trial opens
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestones
The company reported second-quarter revenue of $106.3 million and detailed multiple regulatory and clinical steps across its oncology and immunology pipeline.
SEC filing
Wednesday, August 5
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2
The company cited new drug approvals and an expanded pipeline as it lifted its full-year Portfolio Receipts outlook to $3,400 million to $3,500 million.
SEC filing
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates
New chief executive takes over as company narrows 2026 revenue guidance and reports progress in DM1, FSHD and Huntington's disease programs.
SEC filing
Tuesday, August 4
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOS
Amgen widened its MariTide Phase 3 program, dropped AMG 513, and continued its fight with the FDA over pulling TAVNEOS, while reporting second-quarter results.
SEC filing
Monday, August 3
Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer
The company appointed Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO on August 2, 2026, dividing global deal-making from U.S. and ex-China commercial duties.
SEC filing
Thursday, July 30
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapy
Monday, July 27
Precision BioSciences promotes CFO to COO, names new CFO effective August 1
The Board approved the executive changes on July 23, 2026, and the company announced them in a press release on July 27, 2026.
SEC filing
Friday, July 24
Amgen posts results for three rocatinlimab Phase 3 trials, plus CodeBreak300 and AMG 133 updates
Vir Biotechnology CFO Jason O'Byrne to depart; interim replacement named
O'Byrne will leave his post on August 3, 2026, and Chief Accounting Officer Brent Sabatini will step in as interim principal financial officer.
SEC filing
Thursday, July 23
ImageneBio names Yanina Grant-Huerta as CFO, effective July 20, 2026
The company also disclosed that Chief Medical Officer Benjamin Porter-Brown will shift to a consulting role starting July 24, 2026.
SEC filing
Thursday, July 16
Arcutis adds Mirum CEO Chris Peetz to board of directors
Arcutis Biotherapeutics expanded its board to ten members, naming Mirum Pharmaceuticals co-founder and CEO Christopher Peetz as a new independent Class III director effective July 15, 2026.
SEC filing